Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 38 entries
View as:

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05657613 Org: User:
Start: 01/03/23 End: 06/08/23 Due: 06/08/24

Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00291785 Org: User:
Start: 01/31/04 End: 09/30/08 Due: 09/30/09

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Phase: N/A Priority: Normal
NCT ID: NCT00088530 Org: User:
Start: 07/31/04 End: 07/31/10 Due: 07/31/11

Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02800889 Org: User:
Start: 10/24/16 End: 07/10/18 Due: 07/10/19

Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02807116 Org: User:
Start: 01/31/15 End: 02/28/15 Due: 02/28/16

Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02808455 Org: User:
Start: 01/31/15 End: 03/31/15 Due: 03/31/16

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT00020969 Org: User:
Start: 03/31/01 End: 01/31/05 Due: 01/31/06

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04404361 Org: User:
Start: 05/22/20 End: 09/21/21 Due: 09/21/22

Arsenic Trioxide in Treating Patients With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00017433 Org: User:
Start: 01/31/01 End: 01/31/05 Due: 01/31/06

CT-2106 for the Second Line Treatment of Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00291837 Org: User:
Start: 11/30/04 End: 12/31/07 Due: 12/31/08

Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT01632436 Org: User:
Start: 05/31/12 End: 02/28/18 Due: 02/28/19

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Phase: N/A Priority: Normal
NCT ID: NCT04884191 Org: User:
Start: 07/31/17 End: 09/04/19 Due: 09/04/20

Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00054197 Org: User:
Start: 01/31/03 End: 10/31/04 Due: 10/31/05

Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00054184 Org: User:
Start: 01/31/03 End: 10/31/04 Due: 10/31/05

To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02823171 Org: User:
Start: 08/31/15 End: 09/30/15 Due: 09/30/16

CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00004026 Org: User:
Start: 12/31/98 End: 01/31/05 Due: 01/31/06

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00551733 Org: User:
Start: 08/31/07 End: 12/25/07 Due: 12/25/08

PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02807077 Org: User:
Start: 11/30/14 End: 07/31/15 Due: 07/31/16

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT01321541 Org: User:
Start: 04/20/11 End: 09/14/18 Due: 09/14/19

Phase II CT-2103/Carboplatin in Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00069901 Org: User:
Start: 02/28/03 End: 09/30/06 Due: 09/30/07

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00060684 Org: User:
Start: 12/31/01 End: 05/31/07 Due: 05/31/08

Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00054210 Org: User:
Start: 01/31/03 End: 10/31/04 Due: 10/31/05

Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01638442 Org: User:
Start: 06/30/12 End: 09/30/12 Due: 09/30/13

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT02055781 Org: User:
Start: 02/28/14 End: 04/30/16 Due: 04/30/17

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.

Phase: N/A Priority: Normal
NCT ID: NCT00269828 Org: User:
Start: 12/31/05 End: 12/31/06 Due: 12/31/07